These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

300 related articles for article (PubMed ID: 24011886)

  • 1. Effects of antipsychotic medications on appetite, weight, and insulin resistance.
    Deng C
    Endocrinol Metab Clin North Am; 2013 Sep; 42(3):545-63. PubMed ID: 24011886
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Obesity and related metabolic abnormalities during antipsychotic drug administration: mechanisms, management and research perspectives.
    Baptista T; Kin NM; Beaulieu S; de Baptista EA
    Pharmacopsychiatry; 2002 Nov; 35(6):205-19. PubMed ID: 12518268
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Abnormalities of glucose metabolism associated with atypical antipsychotic drugs.
    Newcomer JW
    J Clin Psychiatry; 2004; 65 Suppl 18():36-46. PubMed ID: 15600383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Which comes first: atypical antipsychotic treatment or cardiometabolic risk?
    Stahl SM; Mignon L; Meyer JM
    Acta Psychiatr Scand; 2009 Mar; 119(3):171-9. PubMed ID: 19178394
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hyperglycemia and antipsychotic medications.
    Haupt DW; Newcomer JW
    J Clin Psychiatry; 2001; 62 Suppl 27():15-26; discussion 40-1. PubMed ID: 11806485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Structural contributions of antipsychotic drugs to their therapeutic profiles and metabolic side effects.
    Jafari S; Fernandez-Enright F; Huang XF
    J Neurochem; 2012 Feb; 120(3):371-84. PubMed ID: 22103329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease.
    Teff KL; Rickels MR; Grudziak J; Fuller C; Nguyen HL; Rickels K
    Diabetes; 2013 Sep; 62(9):3232-40. PubMed ID: 23835329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Metabolic risk during antipsychotic treatment.
    Newcomer JW
    Clin Ther; 2004 Dec; 26(12):1936-46. PubMed ID: 15823759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The implications of weight changes with antipsychotic treatment.
    Sussman N
    J Clin Psychopharmacol; 2003 Jun; 23(3 Suppl 1):S21-6. PubMed ID: 12832946
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Psychotropic drugs induced weight gain: a review of the literature concerning epidemiological data, mechanisms and management].
    Ruetsch O; Viala A; Bardou H; Martin P; Vacheron MN
    Encephale; 2005; 31(4 Pt 1):507-16. PubMed ID: 16389718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug induced weight gain, an impediment to successful pharmacotherapy: focus on antipsychotics.
    Baptista T; Zárate J; Joober R; Colasante C; Beaulieu S; Páez X; Hernández L
    Curr Drug Targets; 2004 Apr; 5(3):279-99. PubMed ID: 15058313
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Distinct endocrine effects of chronic haloperidol or risperidone administration in male rats.
    Lin EJ; Lee NJ; Slack K; Karl T; Duffy L; O'brien E; Matsumoto I; Dedova I; Herzog H; Sainsbury A
    Neuropharmacology; 2006 Dec; 51(7-8):1129-36. PubMed ID: 16919686
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Atypical antipsychotic induced weight gain and metabolic disorders].
    Rojas G P; Poblete A C; Orellana G X; Rouliez A K; Liberman G C
    Rev Med Chil; 2009 Jan; 137(1):106-14. PubMed ID: 19399331
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Drawing up guidelines for the attendance of physical health of patients with severe mental illness].
    Saravane D; Feve B; Frances Y; Corruble E; Lancon C; Chanson P; Maison P; Terra JL; Azorin JM;
    Encephale; 2009 Sep; 35(4):330-9. PubMed ID: 19748369
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metformin for atypical antipsychotic-induced weight gain and glucose metabolism dysregulation: review of the literature and clinical suggestions.
    Hasnain M; Vieweg WV; Fredrickson SK
    CNS Drugs; 2010 Mar; 24(3):193-206. PubMed ID: 20155995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weight gain and glucose and lipid metabolism disturbances during antipsychotic medication: a review.
    Koponen H; Saari K; Savolainen M; Isohanni M
    Eur Arch Psychiatry Clin Neurosci; 2002 Dec; 252(6):294-8. PubMed ID: 12563538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antipsychotic medications: metabolic and cardiovascular risk.
    Newcomer JW
    J Clin Psychiatry; 2007; 68 Suppl 4():8-13. PubMed ID: 17539694
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The metabolic syndrome during atypical antipsychotic drug treatment: mechanisms and management.
    Baptista T; De Mendoza S; Beaulieu S; Bermúdez A; Martinez M
    Metab Syndr Relat Disord; 2004; 2(4):290-307. PubMed ID: 18370698
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of atypical antipsychotic drug-induced weight gain: focus on metformin.
    Miller LJ
    Pharmacotherapy; 2009 Jun; 29(6):725-35. PubMed ID: 19476423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The metabolic effects of antipsychotic medications.
    Newcomer JW; Haupt DW
    Can J Psychiatry; 2006 Jul; 51(8):480-91. PubMed ID: 16933585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.